Company Filing History:
Years Active: 2017-2023
Title: The Innovations of Bent Hojgaard
Introduction
Bent Hojgaard, an innovative inventor based in Allerod, Denmark, is recognized for his contributions to pharmaceutical formulations. With a total of three patents to his name, Hojgaard has made significant strides in the field of oncology, particularly focusing on the delivery of cancer treatments through solid oral dosage forms.
Latest Patents
Among his notable inventions, Bent Hojgaard has recently patented a solid oral dosage form of irinotecan for the treatment of cancer. This innovative composition comprises a compound that can exist as a free base or a salt, along with a mixture that includes a vehicle and a non-ionic surfactant. This combination is designed to achieve effective solubilization, and the formulation typically features an enteric coating to enhance its usability in cancer treatment.
Career Highlights
Hojgaard has gathered experience from working with esteemed companies in the pharmaceutical industry, including Oncoral Pharma ApS and Solural Pharma ApS. His roles in these organizations have facilitated the development of cutting-edge treatments designed to improve patient outcomes in cancer therapy.
Collaborations
Throughout his career, Bent Hojgaard has collaborated with various research institutions and companies, contributing to the advancement of pharmaceutical innovations. His work has provided significant insights into the formulation of drugs that are essential in the fight against cancer.
Conclusion
In summary, Bent Hojgaard stands out as a valuable inventor in the pharmaceutical field. His latest patents reflect a deep commitment to enhancing cancer treatment modalities, demonstrating the impact of innovation in healthcare. As the demand for effective therapies continues to rise, his contributions are expected to play a vital role in shaping future treatment options.